Eric M Liotta1, Constantine J Karvellas2, Minjee Kim1, Ayush Batra1, Andrew Naidech1, Shyam Prabhakaran3, Farzaneh A Sorond1, W Taylor Kimberly4, Matthew B Maas1. 1. Division of Stroke and Neurocritical Care, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 2. Division of Gastroenterology, Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Neurology, University of Chicago, Chicago, IL, USA. 4. Department of Neurology, Harvard Medical School, Harvard University, Boston, MA, USA.
Abstract
BACKGROUND AND AIMS: Hepatic encephalopathy (HE) is a leading contributor to morbidity in liver disease. While hyperammonaemia plays a key role, the mechanisms of cerebral toxicity are unclear. We hypothesized that serum hyperosmolality contributes to HE during acute (ALF) and acute-on-chronic liver failure (ACLF) through mechanisms that affect the water and solute composition of the cerebral environment. METHODS: We performed a retrospective analysis of serum osmolality, cerebral spinal fluid (CSF) solute density (specific gravity, determined from computed tomography attenuation) and clinical HE severity (Glasgow Coma Score [GCS]) at the time of intensive care admission in a prospectively identified cohort of liver failure patients with overt HE. RESULTS: Seventy-three patients (39 ALF and 34 ACLF) were included, of whom 28 (38%) were comatose. Serum osmolality (303.9 ± 15.4 mOsm/kg) was elevated despite normal serum sodium (136.6 ± 6.3 mEq/L). Increased osmolality was independently associated with more severe encephalopathy (ordinal adjusted OR 0.26 [95% CI 0.22, 0.31] for higher GCS per standard deviation increase in osmolality) and lower CSF-specific gravity (linear adjusted β = -0.039 [95% CI -0.069, -0.009] Hounsfield unit per 1 mOsm/kg). CONCLUSIONS: In the context of related research, these data suggest that hyperosmolality increases brain exposure to metabolic toxins by blood-brain barrier alteration and may be a unique therapeutic target.
BACKGROUND AND AIMS: Hepatic encephalopathy (HE) is a leading contributor to morbidity in liver disease. While hyperammonaemia plays a key role, the mechanisms of cerebral toxicity are unclear. We hypothesized that serum hyperosmolality contributes to HE during acute (ALF) and acute-on-chronic liver failure (ACLF) through mechanisms that affect the water and solute composition of the cerebral environment. METHODS: We performed a retrospective analysis of serum osmolality, cerebral spinal fluid (CSF) solute density (specific gravity, determined from computed tomography attenuation) and clinical HE severity (Glasgow Coma Score [GCS]) at the time of intensive care admission in a prospectively identified cohort of liver failurepatients with overt HE. RESULTS: Seventy-three patients (39 ALF and 34 ACLF) were included, of whom 28 (38%) were comatose. Serum osmolality (303.9 ± 15.4 mOsm/kg) was elevated despite normal serum sodium (136.6 ± 6.3 mEq/L). Increased osmolality was independently associated with more severe encephalopathy (ordinal adjusted OR 0.26 [95% CI 0.22, 0.31] for higher GCS per standard deviation increase in osmolality) and lower CSF-specific gravity (linear adjusted β = -0.039 [95% CI -0.069, -0.009] Hounsfield unit per 1 mOsm/kg). CONCLUSIONS: In the context of related research, these data suggest that hyperosmolality increases brain exposure to metabolic toxins by blood-brain barrier alteration and may be a unique therapeutic target.
Authors: Rita Garcia-Martinez; Alex Rovira; Juli Alonso; Carlos Jacas; Macarena Simón-Talero; Laia Chavarria; Víctor Vargas; Juan Córdoba Journal: Liver Transpl Date: 2011-01 Impact factor: 5.799
Authors: J S Bajaj; J Cordoba; K D Mullen; P Amodio; D L Shawcross; R F Butterworth; M Y Morgan Journal: Aliment Pharmacol Ther Date: 2011-02-09 Impact factor: 8.171
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682
Authors: Eric M Liotta; Bryan D Lizza; Anna L Romanova; James C Guth; Michael D Berman; Timothy J Carroll; Brandon Francis; Daniel Ganger; Daniela P Ladner; Matthew B Maas; Andrew M Naidech Journal: Crit Care Med Date: 2016-01 Impact factor: 7.598
Authors: Eric M Liotta; Shyam Prabhakaran; Rajbeer S Sangha; Robin A Bush; Alan E Long; Stephen A Trevick; Matthew B Potts; Babak S Jahromi; Minjee Kim; Edward M Manno; Farzaneh A Sorond; Andrew M Naidech; Matthew B Maas Journal: Neurology Date: 2017-07-26 Impact factor: 9.910